
ChondroFiller outcomes and the Longitudinal Lifetime Programme
Patients treated with ChondroFiller show mean IKDC improvement of 32.4 points sustained at 36 months, with 70–85% achieving meaningful symptom relief at 3–5 years and reoperation rates of 3–8%.














